The small ubiquitin-like modifier (SUMO) signaling cascade is critical for gene expression, genome integrity, and cell cycle progression. In this review, we discuss the important role SUMO may play in cancer and how to target SUMO signaling. Recently developed small molecule inhibitors enable therapeutic targeting of the SUMOylation pathway. Blocking SUMOylation not only leads to reduced cancer cell proliferation but also to an increased antitumor immune response by stimulating interferon (IFN) signaling, indicating that SUMOylation inhibitors have a dual mode of action that can be employed in the fight against cancer. The search for tumor types that can be treated with SUMOylation inhibitors is ongoing. Employing SUMO conjugation inhibitory drugs in the years to come has potential as a new therapeutic strategy.
SUMOylation and Its TargetsSmall ubiquitin-like modifiers (SUMOs) are post-translational modifications (PTMs) involved in various cellular processes, including cell cycle progression and the DNA damage response [1]. The conjugation of SUMO proteins to substrate proteins, called SUMOylation, occurs via an enzymatic cascade consisting of a dimeric SUMO-activating enzyme E1 [SAE1/UBA2 (see Glossary)], a single E2 [ubiquitin-conjugating enzyme 9 (UBC9)], and a limited set of E3 ligases. Mammals have up to five SUMO family members. Mature SUMO2 and SUMO3 have 97% sequence similarity, whereas SUMO1 and SUMO2/3 have only 53% sequence similarity. SUMO2 and SUMO3 form chains in an efficient manner via an internal SUMO consensus site [2,3].
HighlightsCell cycle progression is mediated by small ubiquitin-like modifier (SUMO) ylation and blocking SUMOylation consequently inhibits cell cycle progression, particularly during mitosis.